Anti-Amyloid-β Monoclonal Antibodies against Alzheimer’s disease may be
a potential breakthrough for cataract treatment
Abstract
Cataracts are considered the underlying cause of blindness globally.
When the average age of the earth’s population is on the rise,
cataract-induced blindness and visual dysfunction will increase
dramatically. (1) Currently, the only viable treatment for cataracts is
surgery, including removing the opaque lens and replacing it with an
artificial one which has a huge impact on improving the patient’s
quality of life. Undoubtedly, cataracts have far-reaching repercussions
for countries in terms of social and economic burdens, for example, the
increasing rate of automobile accidents due to reduced visual acuity.
(2) Nonetheless, due to the lack of facilities, ophthalmologists, and
funds, surgery is not a choice in developing countries. (3) It should be
noted that posterior capsular opacification is a common complication of
cataracts, and sometimes, a second intervention is necessary. (4)This
research has thrown up many questions in need of further investigation
to find medications that restore full transparency of the lens.